Investors consider value of Cubist's Trius, Optimer buys
This article was originally published in Scrip
Executive Summary
The market has had a full 24 hours to digest the news that Cubist Pharmaceuticals will buy two antibiotic developers to expand its portfolio of hospital-administered medicines, and investors weighed in with pretty clear opinions about the transactions, which will return up to $1.62 billion to Trius Therapeutics and Optimer Pharmaceuticals shareholders.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.